SABRIL
Drug
Lundbeck LLC
Total Payments
$22.8M
Transactions
766
Doctors
449
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $684,750 | 4 | 2 |
| 2023 | $1.3M | 4 | 2 |
| 2022 | $1.8M | 9 | 7 |
| 2021 | $2.0M | 7 | 5 |
| 2020 | $5.7M | 6 | 3 |
| 2019 | $2.9M | 6 | 4 |
| 2018 | $4.1M | 8 | 6 |
| 2017 | $4.4M | 722 | 434 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $19.3M | 32 | 84.5% |
| Unspecified | $3.5M | 1 | 15.3% |
| Honoraria | $19,600 | 121 | 0.1% |
| Food and Beverage | $9,661 | 605 | 0.0% |
| Travel and Lodging | $1,873 | 4 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,440 | 2 | 0.0% |
| Consulting Fee | $528.50 | 1 | 0.0% |
Payments by Type
General
$19.3M
765 transactions
Research
$3.5M
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Preventing Epilepsy using Vigabatrin in Infants with TB Complex (PREVENT Trial), a randomized, double-blind, placebo controlled seizure prevention clinical trial for infants with TSC | Lundbeck LLC | $3.5M | 0 |
Top Doctors Receiving Payments for SABRIL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Neurodevelopmental Disabilities | Los Angeles, CA | $9.7M | 16 |
| , MD | Neurology with Special Qualifications in Child Neurology | Dallas, TX | $9.7M | 16 |
| Unknown | — | Birmingham, AL | $3.5M | 1 |
| , M.D | Neurology | San Francisco, CA | $2,059 | 6 |
| , D.O | Neurology | Louisville, KY | $1,622 | 2 |
| , M.D | Neuro-ophthalmology | Houston, TX | $1,500 | 3 |
| , MD | Neurology | Birmingham, AL | $1,371 | 4 |
| , M.D | Neurology | Fort Wayne, IN | $1,012 | 3 |
| Ahmed Abdelmoity | Neurology with Special Qualifications in Child Neurology | Kansas City, MO | $1,010 | 3 |
| , MD | Neurology with Special Qualifications in Child Neurology | Memphis, TN | $625.00 | 2 |
| , MD | Neurology | — | $528.50 | 1 |
| , M.D | Neurology with Special Qualifications in Child Neurology | San Diego, CA | $274.79 | 8 |
| , M.D | Neurology with Special Qualifications in Child Neurology | San Diego, CA | $190.49 | 9 |
| , MD, PHD | Epilepsy | Littleton, CO | $170.91 | 3 |
| , M.D | Pediatrics | Jackson, MS | $169.80 | 3 |
| , MD | Pediatrics | San Diego, CA | $160.21 | 8 |
| , MD, MS | Neurology | Los Angeles, CA | $156.94 | 5 |
| , M.D | Pediatrics | Durham, NC | $152.52 | 2 |
| , MD | Neurology with Special Qualifications in Child Neurology | Sugar Land, TX | $151.15 | 3 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Oakland, CA | $150.45 | 3 |
| , MD | Neurology with Special Qualifications in Child Neurology | Wichita, KS | $150.12 | 3 |
| , MD | Neurology | Nashville, TN | $149.73 | 2 |
| , M.D | Neurology with Special Qualifications in Child Neurology | San Diego, CA | $144.39 | 2 |
| , MD | Pediatrics | Charlotte, NC | $143.74 | 2 |
| , MD | Neurology with Special Qualifications in Child Neurology | Orlando, FL | $142.60 | 2 |
Ad
Manufacturing Companies
- Lundbeck LLC $22.8M
Product Information
- Type Drug
- Total Payments $22.8M
- Total Doctors 449
- Transactions 766
About SABRIL
SABRIL is a drug associated with $22.8M in payments to 449 healthcare providers, recorded across 766 transactions in the CMS Open Payments database. The primary manufacturer is Lundbeck LLC.
Payment data is available from 2017 to 2024. In 2024, $684,750 was paid across 4 transactions to 2 doctors.
The most common payment nature for SABRIL is "Royalty or License" ($19.3M, 84.5% of total).
SABRIL is associated with 1 research study, including "Preventing Epilepsy using Vigabatrin in Infants with TB Complex (PREVENT Trial), a randomized, double-blind, placebo controlled seizure prevention clinical trial for infants with TSC" ($3.5M).